HUE058196T2 - N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárások - Google Patents
N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárásokInfo
- Publication number
- HUE058196T2 HUE058196T2 HUE18732548A HUE18732548A HUE058196T2 HU E058196 T2 HUE058196 T2 HU E058196T2 HU E18732548 A HUE18732548 A HU E18732548A HU E18732548 A HUE18732548 A HU E18732548A HU E058196 T2 HUE058196 T2 HU E058196T2
- Authority
- HU
- Hungary
- Prior art keywords
- processes
- dimethoxyquinolin
- dicarboxamide
- cyclopropane
- fluorophenyl
- Prior art date
Links
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical class C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511714P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE058196T2 true HUE058196T2 (hu) | 2022-07-28 |
Family
ID=62683441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18732548A HUE058196T2 (hu) | 2017-05-26 | 2018-05-26 | N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárások |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11279675B2 (OSRAM) |
| EP (1) | EP3630726B1 (OSRAM) |
| JP (3) | JP7166292B2 (OSRAM) |
| KR (1) | KR102611445B1 (OSRAM) |
| CN (1) | CN110621662B (OSRAM) |
| AU (1) | AU2018272088C1 (OSRAM) |
| CA (1) | CA3060370A1 (OSRAM) |
| DK (1) | DK3630726T3 (OSRAM) |
| EA (1) | EA039654B1 (OSRAM) |
| ES (1) | ES2909390T3 (OSRAM) |
| HU (1) | HUE058196T2 (OSRAM) |
| IL (1) | IL270780B2 (OSRAM) |
| MA (1) | MA48776A (OSRAM) |
| MX (1) | MX2019012505A (OSRAM) |
| PL (1) | PL3630726T3 (OSRAM) |
| PT (1) | PT3630726T (OSRAM) |
| SG (1) | SG11201909161PA (OSRAM) |
| UA (1) | UA127760C2 (OSRAM) |
| WO (1) | WO2018218233A1 (OSRAM) |
| ZA (1) | ZA201906127B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2939546C (en) * | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EA039654B1 (ru) * | 2017-05-26 | 2022-02-22 | Экселиксис, Инк. | Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования |
| CA3088200A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| JP7509779B2 (ja) | 2018-12-13 | 2024-07-02 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の結晶性形態及び塩形態 |
| CA3139148A1 (en) * | 2019-06-03 | 2020-12-10 | Exelixis, Inc. | Crystalline salt forms of a kinase inhibitor |
| CA3245315A1 (en) | 2022-03-01 | 2023-09-07 | Synthon B.V. | L(+) TARTARIC ACID CABOZANTINIB SALT AND ITS SOLID FORMS |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
| US11814356B1 (en) | 2023-03-29 | 2023-11-14 | Apotex Inc. | Salt of cabozantinib |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| CA2758030C (en) * | 2009-01-16 | 2019-01-08 | Exelixis, Inc. | Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| TWI619495B (zh) | 2010-07-16 | 2018-04-01 | 艾克塞里克斯公司 | Ｃ-ｍｅｔ調節劑醫藥組合物 |
| US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
| EP2621481B2 (en) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases |
| CA2826751C (en) * | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| MX2013012695A (es) | 2011-05-02 | 2014-03-27 | Exelixis Inc | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. |
| KR20140069133A (ko) | 2011-09-22 | 2014-06-09 | 엑셀리시스, 인코포레이티드 | 골다공증의 치료방법 |
| US9535315B2 (en) | 2011-10-31 | 2017-01-03 | Applied Materials, Inc. | Method of fabricating a color filter array using a multilevel structure |
| JP2015505360A (ja) | 2011-11-08 | 2015-02-19 | エクセリクシス， インク． | 癌治療を定量化する方法 |
| MX2014005458A (es) | 2011-11-08 | 2015-04-16 | Exelixis Inc | Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer. |
| CN104649969B (zh) | 2013-11-22 | 2019-02-12 | 广东东阳光药业有限公司 | 一种替尼类药物的盐及其制备方法 |
| CA2939546C (en) * | 2014-02-14 | 2023-01-17 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| EP3145913A1 (en) * | 2014-05-23 | 2017-03-29 | Mylan Laboratories Ltd. | Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base |
| CN104961680B (zh) | 2014-11-07 | 2017-09-12 | 苏州晶云药物科技有限公司 | N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型 |
| CN104961681B (zh) | 2014-11-13 | 2017-06-13 | 苏州晶云药物科技有限公司 | 卡博替尼的粘酸盐及其晶型 |
| EP3274333B1 (en) * | 2015-03-25 | 2019-04-24 | Sandoz AG | Cabozantinib salts and their use as anti-cancer agents |
| ES2716633T3 (es) | 2015-03-25 | 2019-06-13 | Sandoz Ag | Formas cristalinas de fosfato de cabozantinib e hidrocloruro de cabozantinib |
| US10980792B2 (en) * | 2016-09-12 | 2021-04-20 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of Cabozantinib |
| EP3551612A4 (en) * | 2016-12-07 | 2020-08-12 | MSN Laboratories Private Limited, R&D Center | PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE |
| EA039654B1 (ru) * | 2017-05-26 | 2022-02-22 | Экселиксис, Инк. | Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования |
-
2018
- 2018-05-26 EA EA201992803A patent/EA039654B1/ru unknown
- 2018-05-26 AU AU2018272088A patent/AU2018272088C1/en active Active
- 2018-05-26 JP JP2019562380A patent/JP7166292B2/ja active Active
- 2018-05-26 CA CA3060370A patent/CA3060370A1/en active Pending
- 2018-05-26 PL PL18732548T patent/PL3630726T3/pl unknown
- 2018-05-26 UA UAA201912198A patent/UA127760C2/uk unknown
- 2018-05-26 PT PT187325485T patent/PT3630726T/pt unknown
- 2018-05-26 DK DK18732548.5T patent/DK3630726T3/da active
- 2018-05-26 MX MX2019012505A patent/MX2019012505A/es unknown
- 2018-05-26 IL IL270780A patent/IL270780B2/en unknown
- 2018-05-26 KR KR1020197031409A patent/KR102611445B1/ko active Active
- 2018-05-26 SG SG11201909161P patent/SG11201909161PA/en unknown
- 2018-05-26 ES ES18732548T patent/ES2909390T3/es active Active
- 2018-05-26 HU HUE18732548A patent/HUE058196T2/hu unknown
- 2018-05-26 CN CN201880027861.5A patent/CN110621662B/zh active Active
- 2018-05-26 WO PCT/US2018/034784 patent/WO2018218233A1/en not_active Ceased
- 2018-05-26 US US16/617,352 patent/US11279675B2/en active Active
- 2018-05-26 EP EP18732548.5A patent/EP3630726B1/en active Active
- 2018-05-26 MA MA048776A patent/MA48776A/fr unknown
-
2019
- 2019-09-17 ZA ZA2019/06127A patent/ZA201906127B/en unknown
-
2022
- 2022-02-09 US US17/668,098 patent/US11731941B2/en active Active
- 2022-08-09 JP JP2022127094A patent/JP7437460B2/ja active Active
-
2023
- 2023-06-29 US US18/344,267 patent/US12227481B2/en active Active
-
2024
- 2024-02-09 JP JP2024018527A patent/JP7659097B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE058196T2 (hu) | N-{4-[(6,7-dimetoxikinolin-4-il)oxi]fenil}-N'-(4-fluorfenil)ciklopropán-1,1-dikarboxamid kristályos szilárd sói, elõállítási eljárások és alkalmazási eljárások | |
| ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
| HUE050369T2 (hu) | N - ((1,2,3,5,6,7-hexahidro-S-indacen-4-il) -karbamoil)-1-izopropil-1H-pirazol-3-szulfonamid nátrium-sója | |
| SI3713919T1 (sl) | Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida | |
| CY1121071T1 (el) | Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων | |
| IL250239A0 (en) | Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient | |
| MX384868B (es) | Composiciones para tratar atrofia muscular espinal. | |
| BR112015023109A2 (pt) | Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida | |
| EP3981400A4 (en) | Oral capsule and preparation method therefor | |
| AR099354A1 (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos | |
| EA201691850A1 (ru) | Дозирование составов, содержащих кабозантиниб | |
| IL277683A (en) | Mono-salts of 6-aminoquinoline and their uses | |
| EP3373934A4 (en) | CRYSTALLINE FORM OF A SUBSTITUTED CHINOLINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF | |
| MA44672A (fr) | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate | |
| PL3207928T3 (pl) | Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych | |
| HUE071411T2 (hu) | 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloxi}-N-(metilszulfonil)-acetamidot tartalmazó szilárd gyógyászati készítmény | |
| EP3799594A4 (en) | PRODUCTION OF OLIGOSACCHARIDS | |
| EP3419988A4 (en) | NEW PRNA TRIPLE CONNECTIONS | |
| IL281923A (en) | Compositions useful for treating gm1 gangliosidosis | |
| CY1124838T1 (el) | Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου | |
| CY1121581T1 (el) | Υδροβρωμικο αλας n-(4-xλωpo-2-yδpoξy-3-((3s)-3-πιπεριδινυλσουλφονυλ)φαινυλ)-ν'-(3-φθορο-2-μεθυλφαινυλ)ουριας | |
| EP3795153A4 (en) | Hc-1119 formulation, preparation method and use thereof | |
| DK4081502T3 (da) | Co-krystal af ketoprofen og dets fremstilling, farmaceutiske sammensætninger indeholdende samme og anvendelser heraf | |
| IL271658A (en) | New oral formulations of belinostat | |
| EP4194435A4 (en) | Novel cycloalkenone compound or salt thereof |